Ludmila Feghiu

Ludmila Feghiu

Auto-generated profile, based on publicly available information

Ludmila Feghiu

National Epilepsy Center, Chisinau, Republic of Moldova

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Biological Markers in Fundamental and Clinical Medicine (collection of abstracts)
Verified
Journal Article
Open access
PDF file
MSM. Sprincean
M. Sprincean
HHH. Hadjiu
H. Hadjiu
CCC. Calcii
C. Calcii
NLN. Lupusor
N. Lupusor
CGC. Griu
C. Griu
NRNinel Revenco
Ninel Revenco
VASCULAR ENDOTHELIAL GROWTH FACTOR: AN IMPORTANT BIOMARKER IN PEDIATRIC ISCHEMIC STROKE

1 October 2022 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
CCCornelia Calcii
Cornelia Calcii
SHSvetlana Hadjiu
Svetlana Hadjiu
ICIulia Calistru
Iulia Calistru
ACAndrei Calistru
Andrei Calistru
LFLudmila Feghiu
Ludmila Feghiu
SGStanislav Groppa
Stanislav Groppa
Introduction. Peripheral biomarkers have numerous uses in the treatment, prognosis, and pharmacovigilance of epilepsy. Unfortunately, no peripheral biomarker has demonstrated proven efficacy, although several options are being investigated. In this article, we want to analyze the main areas in which peripheral biomarkers can present their usefulness, including participation in the processes of inflammation, dysfunction of the blood-brain barrier, changes in metabolism, hormones, and growth factors. Material and methods. Publications on diagnostic biomarkers of epilepsy were reviewed. References were identified by PubMed, MEDLINE and Scopus search until June 2022, with various combinations of the terms – „epilepsy”, „seizures”, „epileptogenesis”, „biomarkers”, „neuroimaging”, „inflammation”, „status epilepticus”, „prognosis”. A qualitative and analytical study was performed focused on primary studies published in 2020-2022. More than 85 sources were identified and 33 were selected for analysis from the PubMed, MEDLINE, and Scopus online databases. 12 articles, 5 clinical trials, 2 meta-analyses, 7 reviews, and 7 systematic reviews were identified. Results. Screening articles from online databases according to the search criteria, we found 258 titles on molecular and cellular biomarkers in epilepsy highlighted. The final bibliography included 33 sources that summarized that biomarkers of epileptogenesis are expensive and difficult to research, but the identification of biomarkers specific to the entire epileptogenic process, in close proximity to neuronal damage, have demonstrated the possibility of predicting the risk of seizures, epilepsy and resistance to treatment. Conclusions. Epilepsy remains a continuous area of research; a special role is occupied by specific biomarkers of great clinical importance, being necessary for the prognosis of the disease, the risk of neurological sequelae, refractory to anti-epileptic drugs. Thus, their identification could have a significant impact on the clinical course of the disease.

1 May 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
CCCornelia Calcii
Cornelia Calcii
NPNicolae Testemitanu State University of Medicine and Pharmacy
Nicolae Testemitanu State University of Medicine and Pharmacy
SHSvetlana Hadjiu
Svetlana Hadjiu
MSMariana Sprincean
Mariana Sprincean
LFLudmila Feghiu
Ludmila Feghiu
SGStanislav Groppa
Stanislav Groppa
Introduction: Status epilepticus (SE) is a life-threatening neurological emergency requiring immediate medical intervention and is associated with high mortality and morbidity. The aim of this research was evaluation of clinical and etiological profile of refractory status epilepticus (RSE) among children aged between 1 month and 18 years. Material and methods: The study was done between January 1, 2017 and December 24, 2019. All children with the age limits mentioned above, who presented convulsive SE, subsequently with development in refractory status epileptic (RSE), were included in the study. Patients were investigated and evaluated according to a standard protocol. Subsequently, the characteristics of children with RSE and those without an evolution in RSE were compared. Results: 55 children, out of whom 32 boys with SE were enrolled in the study, of which 20 children (36%) developed RSE. Central nervous system (CNS) infections were the most common causes of SE and development of RSE (51% in SE and 53% in RSE, p > 0.05). Noncompliance of antiepileptic medication served as the second cause for evolution of RSE. The overall mortality rate was 10.9%, the chances of death in RSE (20%) being higher than in SE (5.7%). The unfavorable prognosis was seven times higher in children with RSE, compared to children who developed SE. Conclusions: In the management of CNS infections, pediatricians should be aware of the high risk of developing RSE. In addition, the possibility of developing RSE should be considered and promptly managed in an intensive care unit in order to reduce the risk of mortality and morbidity of this severe neurological condition